Genetic variations in several genes, including patatin-like phospholipase domain-containing 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2)), membrane-bound O-acyltransferase structural domain 7 (MBOAT7), glucokinase regulator (GCKR), and hydroxysteroid 17-beta dehydrogenase-13 (HSD17B13), have been recognized as significant factors influencing the onset and progression of MASLD [88]. This evidence concerns the gene GCKR and metabolic dysfunction-associated steatotic liver disease.